US 12016932
Gene editing for hemophilia A with improved factor VIII expression
granted A61KA61K48/005A61K48/0058
Quick answer
US patent 12016932 (Gene editing for hemophilia A with improved factor VIII expression) held by CRISPR THERAPEUTICS AG expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CRISPR THERAPEUTICS AG
- Grant date
- Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K48/005, A61K48/0058, A61K48/0066, A61K48/0075